|
|
|
|
|
Legal status
Patent revoked (after opposition at EPO)
| (51) | INT.CL. | C07H 21/04 | (2006.01) |
| A61K 39/00 | (2006.01) |
| (11) | Number of the document | 3214091 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17153799.6 |
| Date of filing the European patent application | 2011-12-09 | |
| (97) | Date of publication of the European application | 2017-09-06 |
| (45) | Date of publication and mention of the grant of the patent | 2018-10-03 |
| (46) | Date of publication of the claims translation | 2018-12-10 |
| (30) | Number | Date | Country code |
| 421470 P | 2010-12-09 | US | |
| 201161502649 P | 2011-06-29 | US |
| (72) |
JUNE, Carl H., US
LEVINE, Bruce L., US
PORTER, David L., US
KALOS, Michael D., US
MILONE, Michael C., US
|
| (73) |
The Trustees of The University of Pennsylvania,
Center for Technology Transfer 3160 Chestnut Street, Suite 200, Philadelphia PA 19104-6283,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Modifikuotų T ląstelių, turinčių chimerinį antigeno receptorių, panaudojimas vėžio gydymui |
| USE OF CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS TO TREAT CANCER |
| Payment date | Validity (years) | Amount | |
| 2019-11-27 | 9 | 208.00 EUR |
| Patent revoked (after opposition at EPO) | ||
| Invalidation date | 2019-12-19 |